Department of Nuclear Medicine (Xie YT,Zheng R,Liang M),PET-CT Center (Wu N,Zhang WJ,Liang Y,Liu Y,Li XM),Department of Radiation Oncology (Xiao ZF,Zhou ZM,Feng QF,Wang LH,Li YX),National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract： Objective To investigate the prognostic value of metabolic parameters, maximum standard uptake value (SUVmax), metabolic tumour volume (MTV), total lesion glycolysis (TLG), and PET tumor length(PTL), in primary lesions of esophageal cancer on FDG PET-CT imaging in patients receiving radiotherapy or combined radiotherapy. Methods A total of 55 patients with stage Ⅰ-IV esophageal cancer who received PET-CT radiotherapy localization in our hospital from 2006 to 2012 were enrolled. The association of sex, age, primary lesion, TNM stage, SUVmax, MTV, TLG, PTL, and therapeutic methods with the patient’s prognosis was analyzed. The receiver operating characteristic curve was used to determine the cut-off values of SUVmax, MTV, TLG, and PTL, and the patients were divided into higher-value group and lower-value group. The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used for survival difference analysis. Results The median overall survival (OS) time for all patients was 19.1 months (95%CI 8.1-30.1), and the 1-, 2-, 3-, and 4-year OS rates were 59%, 45%, 35%, and 26%, respectively. The group with lower values of SUVmax(<11.4), MTV (<8.27cm3), TLG (<35.21), and PTL (<5.8 cm) had better prognosis than those with higher values (P=0.002, 0.021, 0.044, and 0.000).Conclusions SUVmax, MTV, TLG, and PTL before treatment have certain values in predicting the prognosis of patients with esophageal cancer. Risk stratification can be performed for these patients before radiotherapy according to these parameters, in order to develop individualized treatment regimens and improve prognosis.
Xie Yanting,Zheng Rong,Wu Ning et al. Prognostic value of FDG PET-CT metabolic parameters before treatment in patients with esophageal cancer receiving radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 452-456.
[1]Enzinger PC,Mayer RJ.Esophageal cancer[J].New Engl J Med, 2003,349(23):2241-2252.DOI:10.1056/NEJMra035010. [2]Kato H,Nakajima M,Sohda M,et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer[J].Cancer,2009,115(14):3196-3203.DOI:10.1002/cncr.24399. [3]Kajiwara T,Hiasa Y,Nishina T,et al. Maximum standardized uptake value in 18F-fluoro-2-deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer[J].Mol Clin Oncol,2014,2(2):313-321.DOI:10.3892/mco.2014.238. [4]史冬梅,黄镜.食管癌预后相关因素的研究[J].癌症进展,2009,7(2):146-152,145.DOI:10.3969/j.issn1672-1535.2009.02.009. Shi DM,Huang J.Advances in the prognostic factors of esophagus carcinoma[J].Oncol Progress,2009,7(2):146-152,145.DOI:10.3969/j.issn.1672-1535.2009.02.009. [5]祝淑钗,宋长亮,沈文斌,等.食管癌根治性切除术后患者预后的影响因素分析[J].中华肿瘤杂志,2012,34(4):281-286.DOI:10.3760/cma.j.issn.0253-3766.2012.04.010. Zhu SC,Song CL,Shen WB,et al. Prognostic analysis of clinicopathological factors in patients after radical resection of esophageal carcinoma[J].Chin J Oncol,2012,34(4):281-286.DOI:10.3760/cma.j.issn.0253-3766.2012.04.010. [6]张永贞,王国平,许翊,等.食管癌患者术后预后影响因素分析[J].现代预防医学,2011,38(9):1720-1723. Zhang YZ,Wang GP,Xu Y,et al. Analysis on prognostic factors of patients after curative esophagectomy[J].Mod Prev Med,2011,38(9):1720-1723. [7]Omloo JMT,van Heijl M,Hoekstra OS,et al. FDG-PET parameters as prognostic factor in esophageal cancer patients:a review[J].Ann Surg Oncol,2011,18(12):3338-3352.DOI:10.1245/s10434-011-1732-1. [8]Pan LL,Gu P,Huang G,et al. Prognostic significance of SUV on PET-CT in patients with esophageal cancer:a systematic review and meta-analysis[J].Eur J Gastroenterol Hepatol,2009,21(9):1008-1015.DOI:10.1097/MEG.0b013e328323 d6fa. [9]Suzuki A,Xiao LC,Hayashi Y,et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy[J].Cancer,2011,117(21):4823-4833.DOI:10.1002/cncr.26122. [10]Brown C,Howes B,Jamieson GG,et al. Accuracy of PET-CT in predicting survival in patients with esophageal cancer[J].World J Surg,2012,36(5):1089-1095.DOI:10.1007/s00268-012-1470-y. [11]Hatt M,Visvikis D,Albarghach NM,et al. Prognostic value of FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology[J].Eur J Nucl Med Mol Imaging,2011,38(7):1191-1202.DOI:10.1007/s00259-011-1755-7. [12]Shum WY,Ding HJ,Liang JA,et al. Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery[J].Anticancer Res,2012,32(9):4163-4168. [13]Li YM,Lin Q,Zhao L,et al. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients[J].Asian Pac J Cancer Prev,2014,15(3):1369-1373.DOI:10.7314/APJCP.2014.15.3.1369. [14]Foley KG,Fielding P,Lewis WG,et al. Prognostic significance of novel FDG PET-CT defined tumour variables in patients with oesophageal cancer[J].Eur J Radiol,2014,83(7):1069-1073.DOI:10.1016/j.ejrad.2014.03.031. [15]Hyun SH,Choi JY,Shim YM,et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma[J].Ann Surg Oncol,2010,17(1):115-122.DOI:10.1245/s10434-009-0719-7. [16]朱婉琦.FDG PET-CT预测食管鳞癌淋巴结转移及预后的临床研究[D].济南:济南大学,2011. Zhu WQ.Correlation between lymph node involvements,survival and primary tumor metabolic parameters in patients with esophageal squamous cell carcinoma[D].Jinan:University of Jinan,2011. [17]Eloubeidi MA,Desmond R,Arguedas MR,et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.:the importance of tumor length and lymph node status[J].Cancer,2002,95(7):1434-1443.DOI:10.1002/cncr.10868. [18]Yendamuri S,Swisher SG,Correa AM,et al. Esophageal tumor length is independently associated with long-term survival[J].Cancer,2009,115(3):508-516.DOI:10.1002/cncr.24062. [19]Zeybek A,Erdo Ban A,Gülkesen KH,et al. Significance of tumor length as prognostic factor for esophageal cancer[J].Int Surg,2013,98(3):234-240.DOI:10.9738/INTSURG-D-13-00075.1. [20]Griffiths EA,Brummell Z,Gorthi G,et al. Tumor length as a prognostic factor in esophageal malignancy:univariate and multivariate survival analyses[J].J Surg Oncol,2006,93(4):258-267.DOI:10.1002/jso.20449. [21]袁双虎,于金明,于甬华,等.18F-脱氧葡萄糖PET-CT检测食管癌病变长度的临床价值[J].中华放射肿瘤学杂志,2006,15(5):389-392.DOI:10.3760/j.issn:1004-4221.2006.05.009. Yuan SH,Yu JM,Yu YH,et al. Value of 18FDG PET-CT in defining the length of esophageal cancer[J].Chin J Radiat Oncol,2006,15(5):389-392.DOI:10.3760/j.issn:1004-4221.2006.05.009. [22]Mamede M,El Fakhri G,Abreu-e-Lima P,et al. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation[J].Ann Nucl Med,2007,21(10):553-562.DOI:10.1007/s12149-007-0040-0. [23]Jeganathan R,McGuigan J,Campbell F,et al. Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET-CT images compare with surgical pathology length?[J].Eur J Nucl Med Mol Imaging,2011,38(4):656-662.DOI:10.1007/s00259-010-1670-3. [24]Choi JY,Jang HJ,Shim YM,et al. FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery:prognostic implications[J].J Nucl Med,2004,45(11):1843-1850. [25]Chan DSY,Fielding P,Roberts SA,et al. Prognostic significance of 18-FDG PET-CT and EUS-defined tumour characteristics in patients with oesophageal cancer[J].Clin Radiol,2013,68(4):352-357.DOI:10.1016/j.crad.2012.08.012. [26]Akutsu Y,Matsubara H.The significance of lymph node status as a prognostic factor for esophageal cancer[J].Surg Today,2011,41(9):1190-1195.DOI:10.1007/s00595-011-4542-y. [27]Kim T,Grobmyer SR,Smith R,et al. Esophageal cancer-the five year survivors[J].J Surg Oncol,2011,103(2):179-183.DOI:10.1002/jso.21784.
2016, Vol. 25 
